カルシウム拮抗薬の世界市場レポート 2025年

カルシウム拮抗薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.4％で220億7,000万米ドルに成長します。予測期間の成長は、心血管疾患の世界の負担の増加、個別化医療の動向、ヘルスケアへのアクセスの増加、適応症の拡大、規制当局の承認、市場の拡大に起因すると考えられます。予測期間の主な動向としては、市場成長、技術進歩、競合情勢、競合分析、患者の嗜好や意識などが挙げられます。

カルシウム拮抗薬市場の成長は、心血管疾患の有病率の増加によって促進されると予測されます。心臓や血管に影響を及ぼす心血管疾患はより一般的になっており、カルシウム拮抗薬（CCB）などの介入に対する需要の高まりにつながっています。これらの薬剤は心不全や脳卒中のリスクを軽減するために使用されます。米国心臓病学会の2022年8月の報告では、米国では2025年から2060年にかけて心血管危険因子が増加すると予測されています。特に糖尿病は39.3％、脂質異常症は27.6％、高血圧は25.1％、肥満は18.3％増加すると予測されています。脳卒中、心不全、虚血性心疾患、心臓発作を含む心血管系疾患の割合も大幅に増加すると予想されています。このような心血管疾患の急増が、カルシウム拮抗薬市場の成長を牽引しています。

ヘルスケア支出の増加は、将来的にカルシウム拮抗薬市場を促進すると予測されています。ヘルスケア支出には、特定の期間（通常は年間）にヘルスケアサービスや関連活動に充てられる、財政的配分を含む総リソースが含まれます。ヘルスケア支出の増加は、アクセス、手頃な価格、研究開発、全体的な患者ケアを改善することにより、カルシウム拮抗薬市場にとって好都合な環境を作り出し、心血管疾患を効果的に管理するための強固なヘルスケアシステムに貢献します。例えば、2024年7月、米国の専門組織である米国医師会は、2022年の医療費が4.1％増加し、総額4兆5,000億米ドルに達し、一人当たり1万3,493米ドルになると報告しました。したがって、医療費の増加がカルシウム拮抗薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界カルシウム拮抗薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界のカルシウム拮抗薬市場：成長率分析
• 世界のカルシウム拮抗薬市場の実績：規模と成長, 2019-2024
• 世界のカルシウム拮抗薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界カルシウム拮抗薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のカルシウム拮抗薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジヒドロピリジン
• ベンゾチゼピン
• フェニルアルキルアミン
• その他の薬物クラス
• 世界のカルシウム拮抗薬市場疾患の兆候別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高血圧
• 胸痛
• 不整脈
• 世界のカルシウム拮抗薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のカルシウム拮抗薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界のカルシウム拮抗薬市場、ジヒドロピリジンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アムロジピン
• ニフェジピン
• フェロジピン
• ニカルジピン
• イスラジピン
• 世界のカルシウム拮抗薬市場ベンゾジアゼピンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジアゼパム
• 世界のカルシウム拮抗薬市場、フェニルアルキルアミンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベラパミル
• 世界のカルシウム拮抗薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベプリジル
• レルカニジピン
• シルニジピン

第7章 地域別・国別分析

• 世界のカルシウム拮抗薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のカルシウム拮抗薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• カルシウム拮抗薬市場：競合情勢
• カルシウム拮抗薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Lupin Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Cadila Healthcare Limited
• Covis Pharma BV
• Glenmark Pharmaceuticals Inc.
• Amneal Pharmaceuticals LLC
• Sofgen Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Knoll Healthcare Private Limited
• Sanofi S.A.
• Clearsynth Labs Ltd.
• Searle LLC
• Bayer AG
• AstraZeneca plc
• Wyeth-Ayerst Lederle Inc.
• GlaxoSmithKline Plc.
• AbbVie Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• カルシウム拮抗薬市場2029：新たな機会を提供する国
• カルシウム拮抗薬市場2029：新たな機会を提供するセグメント
• カルシウム拮抗薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Calcium channel blockers are medications designed to inhibit calcium from entering the muscle cells in the heart and blood vessels. They are commonly used in the treatment of various conditions such as high blood pressure, angina (chest pain), and irregular heart rhythms.

These drugs belong to different classes including dihydropyridine, benzothiazepine, phenylalkylamine, and others. Dihydropyridines specifically function by blocking calcium channels present in the muscle cells of the heart and arterial blood vessels, thereby reducing the influx of calcium ions into these cells. These medications are indicated for conditions such as hypertension (high blood pressure), chest pain, and certain types of arrhythmias. They are typically administered orally, through parenteral routes, or by other methods, and are utilized by hospitals, homecare settings, specialty clinics, and other end-users for medical purposes.

The calcium channel blocker market research report is one of a series of new reports from The Business Research Company that provides calcium channel blocker market statistics, including calcium channel blocker industry global market size, regional shares, competitors with calcium channel blocker market share, detailed calcium channel blocker market segments, market trends, and opportunities, and any further data you may need to thrive in the calcium channel blocker industry. This calcium channel blocker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The calcium channel blocker market size has grown strongly in recent years. It will grow from $15.56 billion in 2024 to $16.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increased incidence of cardiovascular diseases, aging population, advancements in medical research, changing lifestyles, increased awareness.

The calcium channel blocker market size is expected to see strong growth in the next few years. It will grow to $22.07 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising global burden of cardiovascular diseases, personalized medicine trends, increased access to healthcare, expansion of indications, regulatory approvals and market expansions. Major trends in the forecast period include market growth, technological advancements, regulatory landscape, competitive analysis, patient preferences and awareness.

The growth of the calcium channel blocker market is anticipated to be propelled by the increasing prevalence of cardiovascular diseases. Cardiovascular diseases, affecting the heart or blood vessels, have become more prevalent, leading to a heightened demand for interventions such as calcium channel blockers (CCBs). These medications are employed to reduce the risk of heart failure and stroke. An August 2022 report from the American College of Cardiology predicts a rise in cardiovascular risk factors in the United States between 2025 and 2060. Notably, diabetes is projected to increase by 39.3%, dyslipidemia by 27.6%, hypertension by 25.1%, and obesity by 18.3%. Substantial increases are also expected in cardiovascular disease rates, including stroke, heart failure, ischemic heart disease, and heart attack. This surge in cardiovascular conditions is driving the growth of the calcium channel blocker market.

The growing healthcare expenditure is anticipated to propel the calcium channel blocker market in the future. Healthcare expenditure encompasses the total resources, including financial allocations, dedicated to healthcare services and related activities over a specific period, typically measured annually. Increased healthcare spending creates a conducive environment for the calcium channel blocker market by improving access, affordability, research and development, and overall patient care, thereby contributing to a robust healthcare system for effectively managing cardiovascular conditions. For example, in July 2024, the American Medical Association, a professional organization in the U.S., reported that health expenditures rose by 4.1% in 2022, reaching a total of $4.5 trillion, which translates to $13,493 per person. Hence, the rise in healthcare expenditure is driving the growth of the calcium channel blocker market.

Product innovation emerges as a key trend in the calcium channel blocker market, with major companies emphasizing the development of innovative products to maintain their market position. For example, in June 2022, CMP Pharma, a US-based pharmaceutical manufacturing company, introduced Norliqva, the first and only oral liquid solution of the besylate salt of amlodipine-an extended-release calcium channel blocker. Norliqva addresses the challenges associated with crushing or synthesizing amlodipine tablets, ensuring uniform dosing and bioequivalence. This innovative product caters to patients who require amlodipine but face difficulties with swallowing or are unable to swallow. The focus on product innovation is a testament to the dynamic nature of the calcium channel blocker market and the commitment of major companies to meeting evolving healthcare needs.

Major companies within the calcium channel blocker market are strategically developing innovative products, specifically tablets tailored for the treatment of Pulmonary Arterial Hypertension (PAH). These tablets serve as oral pharmaceutical formulations designed to address the unique medical condition of PAH. In May 2022, Zydus, an India-based pharmaceutical company, achieved approval from the US Food and Drug Administration (FDA) for Selexipag tablets. Selexipag is indicated for use in adults to manage Pulmonary Arterial Hypertension, with the goal of delaying disease progression and reducing the likelihood of hospitalization associated with PAH. As a prostacyclin receptor agonist, this medication contributes to the comprehensive management of PAH.

In November 2023, LXO Group, a France-based pharmaceutical company specializing in non-generic prescription medicines, acquired Nimotop from Bayer for an undisclosed amount. This acquisition is part of LXO Group's strategy to increase its market presence, enhance its product offerings, and foster innovation within the industry. Bayer AG, a Germany-based pharmaceutical and life sciences company, is known for developing calcium channel blockers (CCBs).

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the calcium channel blocker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calcium channel blocker market consists of sales of amlodipine, nicardipine, isradipine, diltiazem, and verapamil drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Calcium Channel Blocker Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on calcium channel blocker market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for calcium channel blocker ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The calcium channel blocker market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Dihydropyridine; Benzothiazepine; Phenylalkylamine; Other Drug Classes
• 2) By Disease Indications: Hypertension; Chest Pain; Arrhythmias
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Dihydropyridine: Amlodipine; Nifedipine; Felodipine; Nicardipine; Isradipine
• 2) By Benzodiazepine: Diazepam
• 3) By Phenylalkylamine: Verapamil
• 4) By Other Drug Classes: Bepridil; Lercanidipine; Cilnidipine
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Novartis AG; Bausch Health Companies Inc.; Lupin Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Calcium Channel Blocker Market Characteristics

3. Calcium Channel Blocker Market Trends And Strategies

4. Calcium Channel Blocker Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Calcium Channel Blocker Growth Analysis And Strategic Analysis Framework

• 5.1. Global Calcium Channel Blocker PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Calcium Channel Blocker Market Growth Rate Analysis
• 5.4. Global Calcium Channel Blocker Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Calcium Channel Blocker Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Calcium Channel Blocker Total Addressable Market (TAM)

6. Calcium Channel Blocker Market Segmentation

• 6.1. Global Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dihydropyridine
• Benzothizepine
• Phenylalkylamine
• Other Drug Classes
• 6.2. Global Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypertension
• Chest Pain
• Arrhythmias
• 6.3. Global Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administration
• 6.4. Global Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.5. Global Calcium Channel Blocker Market, Sub-Segmentation Of Dihydropyridine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amlodipine
• Nifedipine
• Felodipine
• Nicardipine
• Isradipine
• 6.6. Global Calcium Channel Blocker Market, Sub-Segmentation Of Benzodiazepine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diazepam
• 6.7. Global Calcium Channel Blocker Market, Sub-Segmentation Of Phenylalkylamine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Verapamil
• 6.8. Global Calcium Channel Blocker Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bepridil
• Lercanidipine
• Cilnidipine

7. Calcium Channel Blocker Market Regional And Country Analysis

• 7.1. Global Calcium Channel Blocker Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Calcium Channel Blocker Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Calcium Channel Blocker Market

• 8.1. Asia-Pacific Calcium Channel Blocker Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Calcium Channel Blocker Market

• 9.1. China Calcium Channel Blocker Market Overview
• 9.2. China Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Calcium Channel Blocker Market

• 10.1. India Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Calcium Channel Blocker Market

• 11.1. Japan Calcium Channel Blocker Market Overview
• 11.2. Japan Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Calcium Channel Blocker Market

• 12.1. Australia Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Calcium Channel Blocker Market

• 13.1. Indonesia Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Calcium Channel Blocker Market

• 14.1. South Korea Calcium Channel Blocker Market Overview
• 14.2. South Korea Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Calcium Channel Blocker Market

• 15.1. Western Europe Calcium Channel Blocker Market Overview
• 15.2. Western Europe Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Calcium Channel Blocker Market

• 16.1. UK Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Calcium Channel Blocker Market

• 17.1. Germany Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Calcium Channel Blocker Market

• 18.1. France Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Calcium Channel Blocker Market

• 19.1. Italy Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Calcium Channel Blocker Market

• 20.1. Spain Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Calcium Channel Blocker Market

• 21.1. Eastern Europe Calcium Channel Blocker Market Overview
• 21.2. Eastern Europe Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Calcium Channel Blocker Market

• 22.1. Russia Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Calcium Channel Blocker Market

• 23.1. North America Calcium Channel Blocker Market Overview
• 23.2. North America Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Calcium Channel Blocker Market

• 24.1. USA Calcium Channel Blocker Market Overview
• 24.2. USA Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Calcium Channel Blocker Market

• 25.1. Canada Calcium Channel Blocker Market Overview
• 25.2. Canada Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Calcium Channel Blocker Market

• 26.1. South America Calcium Channel Blocker Market Overview
• 26.2. South America Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Calcium Channel Blocker Market

• 27.1. Brazil Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Calcium Channel Blocker Market

• 28.1. Middle East Calcium Channel Blocker Market Overview
• 28.2. Middle East Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Calcium Channel Blocker Market

• 29.1. Africa Calcium Channel Blocker Market Overview
• 29.2. Africa Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Calcium Channel Blocker Market Competitive Landscape And Company Profiles

• 30.1. Calcium Channel Blocker Market Competitive Landscape
• 30.2. Calcium Channel Blocker Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Lupin Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Calcium Channel Blocker Market Other Major And Innovative Companies

• 31.1. Cadila Healthcare Limited
• 31.2. Covis Pharma BV
• 31.3. Glenmark Pharmaceuticals Inc.
• 31.4. Amneal Pharmaceuticals LLC
• 31.5. Sofgen Pharmaceuticals
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Knoll Healthcare Private Limited
• 31.8. Sanofi S.A.
• 31.9. Clearsynth Labs Ltd.
• 31.10. Searle LLC
• 31.11. Bayer AG
• 31.12. AstraZeneca plc
• 31.13. Wyeth-Ayerst Lederle Inc.
• 31.14. GlaxoSmithKline Plc.
• 31.15. AbbVie Inc.

32. Global Calcium Channel Blocker Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Calcium Channel Blocker Market

34. Recent Developments In The Calcium Channel Blocker Market

35. Calcium Channel Blocker Market High Potential Countries, Segments and Strategies

• 35.1 Calcium Channel Blocker Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Calcium Channel Blocker Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Calcium Channel Blocker Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer